Vect-Horus and Servier tie up on CNS oligonucleotide delivery

Vect-Horus, a privately held French drug-delivery specialist, has signed a research evaluation and exclusive licence option agreement with Servier to develop oligonucleotide therapies targeting rare central nervous system diseases. The deal gives the Marseille-based company research fees during an initial evaluation phase, with the prospect of an upfront payment, tiered development and regulatory milestones, and single-digit royalties on net sales should Servier exercise its option and bring a product to market.

The financial terms of the option period and the potential milestone ceiling have not been disclosed. No lead indication or compound has been named, though both parties have pointed to rare neurological and neurodevelopmental disorders as the focus.

The platform

At the heart of the arrangement is Vect-Horus's proprietary VECTrans technology, a molecular vector platform designed to shuttle therapeutic or imaging payloads across biological barriers, including the blood-brain barrier (BBB). Vect-Horus was spun out of the Institute for Neurophysiopathology at Aix Marseille University in 2005 and has since raised approximately 42 million euros in equity and public subsidies. The company employs 45 people, the majority in research and development roles.

Oligonucleotide therapeutics, which include antisense oligonucleotides (ASOs), small interfering RNAs (siRNAs), and related modalities, have demonstrated meaningful clinical utility in peripheral targets but face a well-documented barrier to CNS penetration. Systemic delivery of these molecules to the brain in therapeutically relevant concentrations remains one of the sector's persistent engineering problems. Vect-Horus's approach, validated in animal models using vectorised molecules, is positioned by the company as a route around that constraint.

Alexandre Tokay, co-founder and chief executive of Vect-Horus, said the agreement "further validates the potential of our VECTrans platform to overcome delivery challenges in the CNS and expand therapeutic opportunities for patients suffering from serious neurological diseases."

Market context

The CNS drug-delivery space has attracted considerable attention from both large pharma and specialist biotechs over the past several years. Focused ultrasound, nanoparticle carriers, receptor-mediated transcytosis, and lipid nanoparticle reformulation are among the approaches competing for primacy. Ionis Pharmaceuticals and Wave Life Sciences have each advanced ASO programmes into rare neurological indications, while Alnylam's siRNA franchise, built on liver delivery, has raised the industry's appetite for expanding the modality into other organs, including the brain.

Servier, which is governed by a foundation structure rather than public shareholders, has been building out its neurology portfolio and has indicated a strategic commitment to rare and orphan CNS indications. Nitza Thomasson, Global Head of Neurology at Servier, framed the partnership as bringing "complementary expertise" to bear on a therapeutic area where progress has historically been slow.

For Vect-Horus, the Servier agreement represents a meaningful commercial validation of the VECTrans platform, which has so far been demonstrated in preclinical models. The key near-term milestone for observers will be whether Servier exercises its option after the joint evaluation phase, a decision that will signal how the VECTrans data holds up against the company's own internal delivery benchmarks. The regulatory path for any resulting candidate would be shaped by the orphan drug frameworks in both the European Union and the United States, where incentives for rare neurological programmes remain robust.